Catheter Precision has filed a prospectus to offer 68.07 million common shares. The filing with the US Securities and Exchange Commission (SEC) details the proposed securities offering, which represents a significant capital raise for the company.

The prospectus provides regulatory documentation for the offering, outlining the structure of the transaction. The company intends to issue common shares to the public, with the total number of shares specified in the filing.

Offering Details

The filing specifies the total volume of shares to be offered.

The document serves as the primary regulatory disclosure for the offering, providing necessary information to potential investors. The proceeds from the offering are expected to support the company's corporate objectives.

Catheter Precision, Inc. has secured the allowance of 11 patents covering its heart failure and vascular closure technologies, reinforcing its intellectual property portfolio during ongoing discussions to sell these assets. The new patents include both methods and devices, with eight dedicated to heart failure solutions and three to vascular closure mechanisms. These additions fortify the company's proprietary position in key medical device markets as it explores strategic transactions.

The heart failure patents comprise six issued in the US and two issued in international markets. The vascular closure patents include one issued patent and two allowed applications soon to be issued, all of which are US patents. Among the vascular closure patents is US patent no. 12,622,686, dated May 12, 2026, which pertains to the LockeT product currently marketed in the US and Europe.

David Jenkins, CEO of Catheter Precision, stated that the issuance of these patents validates work conducted over several years. He emphasized that the company now holds a patent library of over fifty patents in critical product areas. Jenkins noted that the new intellectual property enhances the company's offerings and supports active discussions regarding the potential sale of the heart failure and vascular closure technologies.

Patent Breakdown

The following table details the allocation of the newly allowed patents across technology categories and jurisdictions:

Product and Technology Overview

Catheter Precision’s LockeT is a suture retention device designed to assist in wound closure following percutaneous venous punctures. The device is classified as a Class 1 medical device by the FDA and has received CE Mark approval. The company’s heart failure technology is developed through its subsidiary, Cardionomix, which focuses on novel therapies for acute decompensated heart failure (ADHF).